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Abstract
Background: Faecal microbiota transplantation is an emerging therapeutic option,
particularly for the treatment of recurrent Clostridioides difficile infection. Stool
banks that organise recruitment and screening of faeces donors are being embedded
within the regulatory frameworks described in the European Union Tissue and Cells
Directive and the technical guide to the quality and safety of tissue and cells for
human application, published by the European Council.
Objective: Several European and international consensus statements concerning
faecal microbiota transplantation have been issued. While these documents provide
overall guidance,weaim toprovideadetaileddescriptionof all processes that relate to
the collection, handling and clinical application of human donor stool in this document.
Methods: Collaborative subgroups of experts on stool banking drafted concepts for
all domains pertaining to stool banking. During a working group meeting in the
United European Gastroenterology Week 2019 in Barcelona, these concepts were
discussed and finalised to be included in our overall guidance document about faecal
microbiota transplantation.
Results: Aguidance document for all domains pertaining to stool bankingwas created.
This document includes standard operating manuals for several processes involved
with stool banking, such as handling of donor material, storage and donor screening.
Conclusion: The implementation of faecal microbiota transplantation by stool banks
in concordance with our guidance document will enable quality assurance and
guarantee the availability of donor faeces preparations for patients.
K E YWORD S
Clostridioides difficile, faecal microbiota transplantation, legislation, stool bank
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INTRODUCTION
Faecal microbiota transplantation (FMT) has become an established
treatment for recurrent Clostridioides difficile infection (CDI),1–4 and it
appears promising as a treatment modality for other disorders.5 In
order to ensure a safe, accessible and cost‐effective implementation
of FMT, stool banks that provide ready‐to‐use donor faeces prepa-
rations are required. Such stool banks may operate at an institutional,
national or international level and are currently being set up in
different European countries.6,7 To date, FMT and stool banking
protocols vary significantly between institutions, mostly due to the
novelty of this treatment approach and the scarcity of guidelines
addressing FMT and stool banking. A recent international consensus
meeting addressed FMT and stool banking,8 and a British guideline
concerning the use of FMT was published in 2018.9 Based on: (a)
available consensus reports; (b) previous experiences6,7,10,11; and (c)
lessons learned from blood banks,7 an attempt was made to define a
standardised model for stool banks in Europe. In addition, the regu-
latory boundaries that are required for safe and cost‐effective FMT
are outlined. This resulted in a practice‐oriented consensus report
including templates for standard operational procedures and ques-
tionnaires (included in the Appendix in Supporting Information Ma-
terial) that may help to standardise the working plans of stool banks,
and facilitate further implementation and regulation of FMT. In
addition, our report will support clinicians who want to offer this
treatment to their patients.
The statements made throughout this paper are supported by all
working group members and describe minimum requirements. In
addition, country‐specific regulations need to be taken into account
to complement the statements.
METHODS
A multidisciplinary working group was formed with experts from
mainly European countries. Authors of previously published
consensus reports8,9 were invited to participate to prevent in-
consistencies. Based on the working process of stool banks as pre-
viously described,5,6 and the clinical application of FMT, topics to be
addressed were subdivided into five groups. Subgroups were formed
based on the expertise of subgroup members. Subgroup‐specific
literature searches were performed prior to submission of concept
documents addressing the previously defined issues/questions, and
statements were phrased. During a working group meeting at the
United European Gastroenterology Week in Barcelona, 23 October
2019, the concepts were discussed in depth by the entire working
group. Although the aim of the working group was to provide a
manual for stool banking in Europe, and not a guideline, an attempt
was made to grade the evidence to support statements. The GRADE
system (Grades of Recommendation Assessment, Development and
Evaluation) was used to grade the strength of evidence (high/mod-
erate/low/very low) and strength of recommendation (strong/
weak).12 Statements addressing organisational aspects of stool
banking were based on expert opinion or law governed. Of note,
based on the lack of available evidence, most statements are based
on expert opinion. An aggregate document was prepared based on
the individual working group's concept documents and expert input
during the meeting. After additional comments from experts, the
document was finalised and is presented here as a summary. Addi-
tional information, containing questions for subgroups, statements
discussed by the workgroup, practical standard operating procedure
(SOP) templates and questionnaires are available as Supporting In-
formation Material.
Definitions
The definitions used in this paper are mainly based on practice rec-
ommendations by the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) and by the Infectious Diseases Society
of America,1,2 and on the guide to the quality and safety of tissues
and cells for human application (tissue guide) of the European
Council.13
Diarrhoea
Diarrhoea is loose stools at a frequency of three or more per 24 or
fewer consecutive hours.1
CDI
CDI is defined as a combination of compatible signs and symptoms
(diarrhoea, ileus, toxic megacolon) confirmed by microbiological evi-
dence of C. difficile toxin and C. difficile in stools without reasonable
evidence of another cause of diarrhoea or by findings demonstrating
pseudomembranous colitis on endoscopy or histology.1
Treatment response
Treatment response in CDI is present when stool frequency de-
creases to less than three per 24 h (or return to the pre‐existent
defecation frequency) over a period of at least 72 h in combination
with improvement of parameters of disease severity (clinical, labo-
ratory, radiological).
Recurrent CDI
Recurrence is present when CDI reoccurs after the resolution of
symptoms of the previous episode. Recurrence within the first
8 weeks after the onset of the previous episode is mostly due to
relapse, whereas renewed symptoms during long‐term follow‐up may
be due to relapse or reinfection.1
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Refractory CDI
Lack of response to medication after 5 days or more of treatment.
Severe CDI
Severe CDI is defined by CDI in combination with either a white
blood cell count of 15 � 103 μl or greater or a creatinine level 1.5
times or greater of the baseline.2
Complicated CDI
CDI is complicated if at least one of the following signs or symptoms
are present and related to CDI (2): hypotension requiring vasopres-
sors, intensive care unit admission for a complication of CDI, ileus
leading to placement of nasogastric tube, toxic megacolon, colonic
perforation, colectomy or colostomy.
Adverse event
Any untoward occurrence associated with the procurement, testing,
processing, storage or distribution of faecal preparations.
Adverse reaction
Any unintended response, including a communicable disease, in the
donor or the recipient that is associated with the procurement or




FMT is regarded as a medical treatment that is carried out by
registered specialists.9,14,15 Although FMT is not yet uniformly
regulated within Europe, it seems obvious that the voluntarily
donated material (faeces) should be collected, handled and used ac-
cording to the standards defined by the EU Commission in the EU
Tissue and Cells Directive (EUTCD; 2004/23/ec).16,17 Faeces should
be regarded as a substance of human origin and may thus be
considered equal to tissue, as long as no additional modifications
other than those necessary for conservation and/or administration
are made.18 Unfortunately, some countries within the EU have
currently classified donor faeces preparations as a drug, even though
only modifications necessary for conservation and/or administration
are applied. Although classification as a drug may enhance the
commercial environment for microbiome therapeutic drug product
development, classification as a drug will inevitably result in time‐
consuming and costly registration processes, sharp and unjustified
rise in costs and will negatively impact availability and innovation.17
Differentiation between stool banks and FMT services
In general, stool banks need to be differentiated from FMT services.
While stool banks are responsible for the manufacture and distri-
bution of FMT preparations, FMT services are responsible for patient
treatment by the use of FMT preparations. While it is not mandatory,
the organisation of an FMT service may be integrated into that of a
stool bank. In relation to FMT administration, we suggest that the
responsible person should be qualified to treat patients and have a
specialist regristration. Centres offering FMT should accommodate
fully equipped treatment facilities to handle side effects and com-
plications of FMT procedures.
Organisation of stool banks
A stool bank should comply with the following standard
requirements.16,19
Organisational description
The EUTCD requires a documented organisational plan for all
intended activities and the institutional appointment of an overall
responsible person.16 This responsible person should be a registered
medical specialist. The stool bank coordinator should be in charge of
the dedicated personnel, the overall quality control and the reporting
and handling of adverse events and reactions. The organisational plan
should feature a list or a chart of primary implicated partners, their
assigned responsibilities, a description of required personnel, vali-
dation and qualification concepts, audit schedules, equipment and
facilities for each of the three divisions; that is: donor recruitment,
screening and manufacture.
Quality management
Stool banks should implement a quality system in accordance with
the requirements described in detail in the guide to the quality and
safety of tissues and cells for human application (tissue guide) of the
European Council.13 Although the EU Guidelines for Good
Manufacturing Practices (GMP) specifically guide the preparation of
medicinal products, their content contains relevant aspects for tissue
and stool banks as well. Therefore, the recently released fourth
edition of the tissue guide contains good practice guidelines for tissue
establishments including relevant elements of GMP.
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For all activities, SOPs, guidelines, reference manuals, reporting
forms and procedural protocols must be present, and should be
updated continuously. Any substantial change to activities requires
prior written approval from the responsible specialist. Any pro-
cesses that may critically affect the quality or the safety of
donated material must be identified and lead to implementation of
precautionary measures. This includes describing responsible
personnel, SOPs, logging and referencing manuals. All activities
related to the preparation and distribution of donated material
should be logged.
Incidents occurring during donor screening, the laboratory
processing of donated faeces or distribution which may potentially
impact patient outcome should be handled as adverse events and
result in re‐evaluation of (adherence to) protocols. Auditing by local
or preferably (in the future) national authorities should be part of
the quality management of a stool bank. Such audits should ensure
that data are entered and maintained properly, and evaluate the
working processes and quality assurance programme of the stool
bank.
Personnel
All personnel should have clearly defined and documented work
descriptions. To ensure competencies, the personnel should be
trained in relevant hygiene measures, safety procedures, technical
protocols and the organisation before conducting any activities.
Activity
A stool bank should maintain a registry of its activity and should
be able to collect and report data on the patients treated with the
preparations it distributes. Reporting should include the number of
patients, the treatment modality used (colonoscopy, enema, gastric
or duodenal tube, gastroscopy, capsules, etc.), as well as follow‐up
data including safety and outcome of FMT. In the near future,
these data should also be entered into a national or international
registry.
Distribution
The distribution of faecal preparations from a stool bank to an FMT
service requires a (written) agreement between the stool bank and
the FMT service in which each party's responsibilities are stated.
Prior to distribution, the third party must confirm that it is in
possession of sufficient facilities to conduct FMT safely. It is the
duty of the stool bank to evaluate and select third parties. Clinical
application and patient follow‐up is the responsibility of the treating
clinician at the FMT service. The FMT service has to report these
data back to the stool bank as described above (see Section 3.3.4).
SOPs are required for requests of FMT preparations by third‐party
institutions, and clear instructions on how to handle the prepara-
tions should be available. Return policies of preparations from
third‐party institutions should be handled according to a shared
SOP.
Adverse reaction documentation
Adverse events, adverse reactions (ARs) and serious ARs as defined
by the International Council for Harmonisation of Technical Re-
quirements for Pharmaceuticals for Human Use harmonised
tripartite guidelines20 should be documented. The stool bank should
be able to communicate data related to performance, outcome and
safety in an annual report for national health authorities or other
auditing authorities. Quality auditing should be organised in
collaboration with local or national authorities. Complications and
ARs of FMT are generally underreported.21,22 Expected ARs
following FMT include short‐term (including among others abdom-
inal pain, dyspepsia, diarrhoea, fever, constipation) and long‐term
(including postinfectious irritable bowel syndrome) reactions.22 In
addition, unexpected ARs may occur and careful monitoring is
required. A serious AR may be procedure related (such as aspira-
tion, perforation), or not clearly related to the procedure. A
distinction between procedure‐related and unrelated complications
should be made according to established guidelines.23,24 Each stool
bank or FMT service should have a SOP to describe how to handle
serious ARs. In the case of any serious AR that is deemed related to
FMT, the unit is obligated to notify the appropriate authority
immediately. The stool bank is responsible for ensuring notification
to the health authorities and confirming that sufficient actions and
adaptations are being made. All relevant personnel and divisions
should be notified in the case of a serious AR to facilitate trace-
ability and control of quality and safety. Effective and rapid pro-




All data regarding donors and recipients should be anonymised to
maintain a principle of voluntary altruism between donor and re-
cipients without any revealing elements. This also applies to third‐
party data access. All steps of the donation should therefore be
uniquely coded and linked using specific donor identifiers, donation
identifiers and donation product identifiers.
Traceability
An efficient and well protected data storage system for logging
should be in place, allowing accurate tracing of the entire process
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from donor to recipient. Both donor and processing records should
be kept. All data necessary to map the process and handling should
be kept for a minimum of 30 years.
Storage
Paper‐based documentation systems are acceptable, but secure
electronic systems that are auditable, traceable and retrievable are
preferred. Storage must be in accordance with local data protection
regulations.
DONOR RECRUITMENT, SELECTION AND
SCREENING
Donor recruitment
Donation of stool is a voluntary act and should not become a subject
of trade. The use of unpaid donors reduces the risk that applicants
withhold information during the screening process. Reimbursement
of expenses for travel to the donation centre is reasonable. Universal
donors are preferred over patient‐selected donors. In individual
cases, a patient‐selected donor may be accepted, if (s)he fulfils all
criteria determined in the screening process for universal donors.
Healthcare workers may be approved as donors if they fulfil all
necessary requirements, although some stool banks choose to
exclude them because of a potential risk of multidrug resistant or-
ganism carriership.
Donor informed consent
All donors should be informed about the associated risks and benefits
and provide written informed consent that covers the provision of
personal information, the screening processes, the provision of mul-
tiple donations, the storage of donor data in a donor registry and
future unscheduled contacts by the stool bank in case of adverse
events or for research purposes. A proposed template for an
informed consent form for healthy donors is included in the Appendix
in Supporting Information Material.
Donor screening
Donor screening should be conducted in accordance with a locally
approved set of SOPs and performed by dedicated staff. Meetings
between the donor screening staff and the rest of the stool bank
team need to be scheduled on a regular basis, in order to identify
problems with respect to screening or the availability of donations
well in advance. The collected data should be documented on pre-
specified forms that facilitate the structured display of results ob-
tained during the screening process (interviews/questionnaires and
microbiological testing) and include documentation of donor
clearance.
Initial questionnaire
During the first step of the screening process, the medical history and
risk behaviour of potential donors should be assessed by the use of a
dedicated questionnaire. The results should be evaluated by a clini-
cian. Objective evaluation should include a document clearly identi-
fying the consequence of a specific response for the screening
process. The topics and items that should be addressed in this
questionnaire are listed in Table 1. A proposed questionnaire with
consequences for positive answers is added to the Appendix (Sup-
porting Information Material).
Microbiological testing
Once a potential donor has been found suitable for further evalua-
tion based on the donor questionnaire and the physical examination,
he or she should undergo blood and faeces screening for trans-
missible pathogens listed in Table 1.
Stool donation, quarantine and retesting of donors
Once a donor has been approved, (s)he should complete a second
short questionnaire before each donation, assessing the occurrence
of any event that may have occurred between donor approval and
donation. Complete donor screening based on blood and faecal an-
alyses should be repeated a minimum of every 3 months. A donation
period should have a defined maximum duration, not exceeding
3 months and should start and end with a complete donor screening.
Blood tests pertaining to the close‐out screening should be per-
formed a minimum of 4 weeks after the last donation to allow for a
lag time of serology or polymerase chain reaction‐based testing for
certain pathogens. FMT products prepared during a donation period
should be put under quarantine until the repeat donor screening
results are available.
If donor screening is performed as recommended in this docu-
ment, direct testing of each preparation is not mandatory. It may,
however, be required by local regulations.
Donor screening for treatment of patients with severe
immunosuppression
A distinction should be made between severely immunocompromised
and moderately immunocompromised patients, as outlined in the
section describing the clinical application of FMT below. FMT prep-
arations for severely immunocompromised patients should be made
with the following additional safety precautions:
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1. Additional screening tests are advised for the use of FMT prep-
arations in severely immunocompromised patients (see Table 2
and Supporting Information Material 2).
2. FMT products should be put under quarantine until the donor has
been found acceptable in a repeat screen. For severely immuno-
compromised patients (see paragraph ahead about the clinical
TAB L E 1 Items to be assessed during screening of donors before approval for FMT
Infectious diseases
� History or exposure to infectious diseases with chronic activity: HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV), non
� successfully eradicated helicobacter pylori, syphilis, malaria, trypanosomiasis, tuberculosis, Chagas disease,
� strongyloidiasis
� Any currently active infection or those of relevance within the past 6 months
� Live attenuated vaccine within the past 8 weeks
� Country of birth
At‐risk behaviour
� Current or previous intravenous drug use
� Ongoing high risk sexual behaviour within the past 6 months
� Travel to high‐risk foreign countries within the past 6 months
� Current occupation in a setting facilitating acquisition of potential pathogens (e.g., veterinarian, animal attendant, gamekeeper, prison worker)
� Tattoo, piercing or acupuncture within the past 6 months
� Major surgery within the past 6 months
� Contact with human blood (e.g., accident, needle stick injury) within the past 6 months
� Previous prison term
� Previous tissue/organ transplantation
� Transfusion of blood products (e.g., packed red cells, plasma, platelets, immunoglobulins) within the past 6‐month medical history
Medical history
� Chronic diseases
� (Risk of) Creutzfeldt–Jakob disease
� Allergies or atopy (e.g., food or drug allergies, asthma)
� hospitalisation within the past 4 months
� Ongoing pregnancy
� Antibiotic treatments, scheduled or received within the past 3 months
� Regular medication or nutritional supplements
� BMI (accepted if ≥20 and ≤25 kg/m2)a
� Age (accepted if ≥18 and ≤60 years)
Intestinal health
� Previous or scheduled gastrointestinal surgery, except for appendectomy
� Gastrointestinal symptoms within the past 3 months (e.g., diarrhoea, constipation, haematochezia, vomiting, abdominal pain), or (removed)
adenomatous polyps or sessile serrated lesions
� Any other relevant clinical sign or symptom within the past 3 months (e.g., fever or rash)
Note: Exclusion criteria related to each item are presented in Supporting Information Material 3.
Abbreviations: BMI, body mass index; FMT, faecal microbiota transplantation.
aSome stool banks accept donors with a BMI more than >18 and less than <30 kg/m2.
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application of FMT), the prepared FMT preparation itself should
undergo a quality control that includes (re)screening for potential
pathogens, as listed in Table 2.
PROCESSING AND STORAGE OF DONOR FAECES
PREPARATIONS
Donor faeces collection and preparation for FMT should follow a
standard protocol to ensure that products are consistently produced
and controlled with respect to the quality standards appropriate to
their intended use. The process described below is based on expe-
riences in different centres and has not been tested rigorously. There
are no reported studies comparing different preparation protocols of
faecal preparations. A possible protocol is presented in Table 3.
Following a standard protocol enables the comparison of outcomes
between institutions, facilitating quality assurance. The described
protocol has proved effective for FMT treatment of recurrent CDI;
for other potential indications, adjustment of the protocol may be
required in the future.
Collection of donor stool
To promote standardised practice and a safe and effective product,
clear written instructions should be provided to the donor for faeces
collection and delivery procedures. To prevent environmental/cross‐
contamination, faeces is collected by the donor in a faecal container
for single use only (e.g., fecotainer).
Donors should hand in their faeces within 2 h after defecation;
some stool banks prefer on‐site donation. After defecation and until
further processing, the stool sample can be stored at room temper-
ature. If it takes more than 30 min to deliver the collected faeces to
the stool bank, temporary storage in a cooler bag or refrigerator is
preferred because faecal storage without stabilisation buffer signifi-
cantly changes taxa abundances from 30 min onwards.28–31
Processing of preparations
In most studies that performed FMT for recurrent CDI, donor faeces
was processed within 6 h of defecation.4,11,25–27,32–48 Studies in which
a longer interval between defecation and processing was allowed (24–
48 h) report a somewhat lower cure rate of FMT (approximately
75%).49–52 In addition, it is hypothesised that a high viability of bacteria
in donor stool increases the efficacy of FMT. Subsequently, this could
allow a reduced amount of donor faeces used per suspension. To
minimise sample degradation and alteration, donor faeces should be
processed as soon as possible as most faecal bacteria are anaerobic.
The preparation of faecal preparations under aerobic conditions
is considered suitable for FMT treatment of recurrent CDI, as
anaerobic processing does not increase cure rate.53–55 This
TAB L E 2 Blood and faeces tests for donor screening before approval for FMT
Stool analyses
� Bacterial enteral pathogens: Shiga‐like toxin‐producing E. coli (STEC) stx1/stx2,a Shigella spp., campylobacter jejuni and coli, Salmonella spp.,
Yersinia enterocolitica and Clostridioides difficile (all PCR), Helicobacter pylori (faecal antigen), Vibrio species (if visited or residing in tropical
country within the past 6 months; culture)
� Antibiotic‐resistant bacteria: Extended spectrum beta‐lactamase‐producing bacteria (ESBLs)/multidrug‐resistant Gram‐negative bacteria
(MRGN) including carbapenemase‐producing enterobacteriales, vancomycin‐resistant enterococci (VRE), methicillin‐resistant staphylococcus
aureus (MRSA; all culture)
� Viruses: norovirus, rotavirus (all PCR), SARS‐CoV‐2b
� Parasites: Cryptosporidium spp., Giardia lamblia, helminths, Entamoeba histolytica, Dientamoeba fragilis, strongyloides stercoralis (PCR), cyclospora
and Isospora,c Blastocystis hominisd (PCR, antigen (if available) or microscopy)
Blood analyses
� General laboratory: CRP, creatinine, ALT, bilirubin, blood cell count
� Viruses: hepatitis A (IgM), hepatitis B (HbsAg), hepatitis C (anti HCV), HIV 1 and 2 (combined HIV antigen/antibody test), HEV serology, SARS‐
CoV‐2b
� Bacteria: Treponema pallidum (TPHA)
Additional screening tests advised for immunocompromised patients (see Supporting Information Material 8): Stool: Plesiomonas shigelloides,
adenovirus, parechovirus, astrovirus, enterovirus, sapovirus, microsporidia. Blood: CMV, EBV, toxoplasmosis.
Abbreviations: ALT, alanine aminotransferase; CMV, cytomegalovirus; CRP, C‐reactive protein; EBV, Epstein–Barr virus; FMT, faecal microbiota
transplantation; PCR, polymerase chain reaction.
aEnteropathogenic Escherichia coli (EPEC) testing may be considered in some countries.
bCovid‐19 (SARS‐CoV‐2) testing of asymptomatic donors combining serology and stool testing requires further validation.
cIf residing in or foreign travel to tropical country within the past 6 months.
dKolonisation with Blastocystis hominis is not considered an exclusion criterium. However, the working group advises to monitor for the effects of
transmission.
eSeveral stool banks also include HTLV 1 and 2 testing.
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observation may be explained by the fact that a considerable part of
the bacterial genera can tolerate oxygen for a limited amount of time
or produce resilient spores that allow transfer of at least a proportion
of anaerobic intestinal bacteria.56
Pooling (mixing) of multiple donor faeces during processing is not
recommended because: (a) it hampers the traceability of the faecal
preparation to the individual donor; (b) the risk of transmissible
disease may be increased; and (c) the principle of transfusing a
balanced microbiota preparation may be lost.
It is preferable to use 50 g or more of stool to prepare an FMT
suspension for recurrent CDI treatment. Systematic reviews suggest
that the use of 50 g or more of faeces is more effective than less than
50 g.57,58 However, the strength of this recommendation is impaired
by the absence of comparative studies, limited numbers of recent
studies and variation in delivery routes. Several experts report
(mostly unpublished) positive results with less than 50 g of donor
faeces.59 Reducing the amount to 25 g (or even lower) could there-
fore be considered but should be validated.
In general, the faecal suspension is made with preservative‐free
sterile 0.9% saline as diluent.4,11,26,32,34–38,40–43,47–50,55,60–75 The
suspension should not be too viscous for infusion through a naso-
duodenal tube or biopsy channel of a gastroscope or colonoscope.
The suspension can be homogenised by a variety of
methods such as blenders,32,35–37,42–44,46,50,53,55,60,61,65,67,69,73,74
stomachers34,51,71 with mortar and pestle,6 or wooden spat-
ulas.26,49,76 Of utmost importance is the use of clean consumables,
which implies that materials should be decontaminated using a vali-
dated method if reused or should be disposable. To prevent clogging
of the tube/biopsy channel during the administration procedure the
faecal suspension should be filtered. Filtration can be performed by a
gauze, filter paper, strainers or sieves. To prevent external contam-
ination either a closed system or an open system in a biological safety
cabinet is preferred. To combine homogenisation and filtration, a bag
mixer appears easy to handle and is efficient.
The infused volume may be reduced using centrifugation,6,55,61,74
but the reported cure rate of 68% after multiple centrifugation and
washing steps appears relatively low,41 and such an approach should
be validated.
To prepare frozen preparations, a cryoprotective agent
should be added prior to freezing. In general, the
cryoprotectant glycerol is used in a final concentration of 10%–
15%.26,27,34,41,53,55,61,66,69,71,73,74,77 Cryopreservation is a process of
preservation of the biological and structural functions of tissues or
cells when cooling to sub‐zero temperatures. The viability of six
representative groups of faecal bacteria after 6 months of storage at
80°C in normal saline with 10% glycerol did not differ from baseline,
whereas viability was reduced in suspensions stored without glyc-
erol.41 A possible side effect of large amounts of glycerol in the bowel
TAB L E 3 Validated standardised conditions for processing of FMT suspensions and treatment of patients with recurrent Clostridioides
difficile infection
Processing of FMT suspensions
Amount of faeces 50 ga
Processing Aerobic or anaerobic
Diluent NaCl 0.9%
Cryoprotectant Glycerol 10%
End volume 50–60 g: 200 cc
25–30 g: 100 cc
Storage −80°C, maximum 2 years
Timeframe between collection and storage <6 h (rapid processing preferred)
Treatment of patients
FMT preparation Frozen stool banked preparation
Pretreatment of patient 4–10 Days vancomycin 125–250 mg qid (or fidaxomicin 200 mg bid)
Stop >24 h before FMT
Bowel lavage with macrogol on day before FMT
(Not necessary in case of capsule administration)b
Colonoscopy
Nasoduonal tube (infusion 10–25 cc/minute)
Capsules, if established protocol
Abbreviations: CDI, Clostridioides difficile infection; FMT, faecal microbiota transplantation.
aSuspensions made of 25‐g donor faeces may even suffice, but require validation.25–27
bFor upper gastrointestinal delivery for treatment of CDI, bowel lavage could be limited to 50% of the advised dose for colonoscopy cleansing.
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is a mild alteration in serum glucose. This is not observed with doses
below 0.75 g of glycerol per kg body weight.78 A faeces preparation
of 200 cc, containing 10% glycerol (approximately 20 g) is far below
this limit.
Encapsulation of glycerol preparations and cryopreservation of
encapsulated donor faeces is feasible and could reduce the burden of
FMT for patients in the future, but requires further validation.79
Storage of FMT preparations
FMT preparations should be stored in sealed, clean plastic containers,
with a unique code ensuring traceability of the sample (see data
management). Storage of FMT preparations (intended for treatment)
should be accommodated by the stool bank in a dedicated 80°C
freezer with connected alarm notification to guarantee continuous
registration of the storage conditions. Documentation requires a
biobanking information and management system for coding, regis-
trations and tracing of the samples.
All processed FMT preparations should be placed into quaran-
tine and stored in clearly distinguishable sections until all donor
screening results are available. The release of products must be
documented, and following these quarantine measures, the FMT
preparations should be cleared and transferred to another distinct
storage section. Only cleared FMT preparations should be used for
patient treatment.
Distribution of FMT preparations should be performed on dry
ice (or 4°C or room temperature in the case of immediate use after
transfer) shipment through a certified courier service. Registration in
a “biobanking information and management system” related data-
base for the shipped faecal preparations, including recipient insti-
tution and requestor information, should be undertaken so that
biovigilance tracing can be performed in case of ARs. Long‐term
storage of faecal preparations at the recipient centre should be
discouraged.
To ensure the maximum safety and quality of the FMT prepa-
ration, it is mandatory to specify a maximum storage time with an
expiry date. The association between storage conditions and clinical
efficacy has not been investigated. Storage at −80°C is preferred,
although storage of faecal preparations at −20°C for up to one month
(30 days) may not reduce efficacy.80 In general, long‐term storage
should be at −80°C or lower to prevent sample degradation. Once
preparations are transferred to a ward or an endoscopy unit for
administration, temporary storage at −20°C is acceptable. High cure
rates have been reported, with frozen FMT suspensions stored up to
10 months at −80°C6,26,27,34,53,55,73,74 but this could in theory be
much longer. OpenBiome and The Netherlands Donor Feces Bank
have good experiences with storage up to 1 and 2 years,
respectively.6,81
A sample of the original donor faeces and/or of the processed
FMT preparation should be stored for a minimum of 10 years
following the application for retrospective quality assessment in case
of an AR.
Thawing of donor faeces preparations
Thaw times depend on the volume and type of FMT preparations. A
200‐cc suspension can be thawed overnight in a 4°C refrigerator, or
during 5 h at room temperature. Warm water baths (37°C) can be
used to speed up thawing of FMT suspensions, but are not applicable
to the thawing of capsules. However, only clean water baths with
fresh water should be used to avoid cross‐contamination (especially
with water‐dwelling bacteria such as Pseudomonas). Thawed faecal
suspensions should be infused the same day, and should not be
refrozen, because freeze thaw cycles adversely affect the viability of
the microbial communities in the faecal suspension.82
The faecal suspension should be at room temperature when
infused into the recipient, to minimise abdominal discomfort.
CLINICAL APPLICATION OF FMT
The primary aim of a stool bank is to centralise the process of donor
screening and processing and storage of donor faeces preparations.
Given the novelty of this treatment modality, guidance for treating
physicians may be required to optimise the safety and efficacy of
large‐scale FMT implementation. Stool banks can offer expert
consultation at the request of the treating physician, or they can
incorporate consultation as part of a standard procedure to verify the
correct indication for FMT before delivering FMT preparations.
Currently, stool preparations are indicated for recurrent CDI only. In
a research or compassionate use setting, other indications could be
considered. Stool should not be sold or delivered to patients upon
their own request. Finally, the need for documentation and quality
improvement requires a strong and well‐defined infrastructure.
Consultation
To offer appropriate consultation, an expert panel is required. As
indications for FMT are likely to become more numerous in the
future, medical specialists in the field pertaining to the added in-
dications should be included in the FMT expert panel of a stool
bank. A standardised patient questionnaire with key information
about the current episode of CDI, previous episodes of CDI,
treatment effects and microbiological testing is required (see
Supporting Information Material 8). The expert panel may assess
whether the indication is appropriate and advise about additional
diagnostics or an alternative therapy. Based on such a consultation
process, The Netherlands Donor Feces Bank has rejected about a
quarter of the requests for FMT preparations for treatment of
recurrent CDI.6 An even higher rate of inappropriate FMT in-
dications (around 50%) was noticed by a French reference centre
(St Antoine Hospital). If regular consultation is not offered by a
stool bank, treating clinicians should receive contact information
for consultation in case of: (a) unexpected problems during the
FMT treatment; and (b) unexpected ARs.
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Patient data should be shared and stored appropriately, in
accordance with European General Data Protection Regulation
guidance and other local regulations.
Treatment protocol
A standardised treatment protocol for recurrent CDI will enable
the comparison of outcomes among FMT centres, and subse-
quently increase safety and facilitate quality assurance. However,
variation of almost all steps of the FMT treatment protocol is
conceivable. Therefore, a validated treatment protocol is presented
in Table 3.
Pretreatment of patients
In clinical practice, antibiotics are initiated directly after a positive
C. difficile test. It is unknown if pretreatment with antibiotics in-
creases the effectiveness of FMT, but most centres perform FMT
following at least 4 days of oral vancomycin (125–250 mg qid) or
fidaxomicin (200 mg bid). Antibiotics should be stopped the day
before FMT (>24 h before FMT). Bowel lavage is required before
a colonoscopy. In general, (modified) bowel cleansing is also per-
formed one day before donor faeces infusion via the upper
gastrointestinal route; this could for example include 2 instead of
4 l polyethylene glycol‐electrolyte lavage solution.6 Whether bowel
lavage increases clinical efficacy for the treatment of CDI is
unknown.
Administration method
In a small study, FMT via a nasoenteric tube (upper gastrointes-
tinal delivery) or colonoscopy (lower gastrointestinal delivery) ap-
pears equally effective (p = 0.53).74 In addition, nasogastric
administration is possible after pretreatment with proton pump
inhibitors.35 One study suggested that treatment with enemas
more often requires repeated infusions,49 but this study used low
volume enemas (50 ml) and no bowel lavage. Capsules containing
either lyophilised or glycerol‐preserved faeces suspensions also
appear effective.62,79 The choice for the route of delivery should
be based on local preferences and patient characteristics, if
applicable. A volume of 200 cc can be safely infused via the upper
gastrointestinal route. Slow infusion of the donor faeces suspen-
sion (e.g., 10–25 cc/minute) may prevent nausea and regurgitation/
aspiration. In patients with impaired gastrointestinal motility,
infusion through a colonoscope is preferred to prevent regurgita-
tion/aspiration. Moreover, upper gastrointestinal delivery (including
capsules) should be avoided in patients with swallowing disorders,
because of the increased risk of aspiration. Small intestinal bac-
terial overgrowth has not been recognised as an adverse event of
upper gastrointestinal delivery of FMT. In frail patients,
ileocolonoscopy can be avoided by upper gastrointestinal delivery,
rectosigmoidoscopy or enema. The infusion of the donor faeces
suspension is straightforward and can be performed by any
appropriately qualified healthcare professional.
Indications and contraindications for FMT
The development of national and international guidelines for the
clinical applications of FMT is a dynamic process, driven by the
emerging body of clinical evidence. The indications and contraindi-
cations outlined below represent the consensus of the working
group.
Indications
FMT should be considered in patients with two or more CDI re-
currences. A balance of risks and benefits should guide a joint
decision of either FMT or (tapered) antibiotics with or without
additional treatment with, for example, monoclonal antibody or
nonabsorbable antibiotics. Few studies have addressed the effects
of FMT in patients with refractory or severe CDI, although FMT as
rescue treatment appears encouraging.40,63,83–86 We suggest
FMT as an option for patients with refractory or severe CDI. The
route of FMT application in severely ill patients should be guided
by the complication risk of the individual patient. Toxic megacolon
should mainly be treated surgically. In patients with fulminant
disease, a diverting ileostomy or other surgical treatment options
should be considered. In patients who refuse surgery, or in whom
surgery is somehow contraindicated, FMT via the lower or upper
gastrointestinal route can be cautiously considered and has resul-
ted in cure.45,53 Because the efficacy of FMT in severe and
complicated CDI appears lower, repeated infusions are often
required.
Contraindications
Currently, no data from clinical studies or reviews indicate abso-
lute contraindications for FMT. Based on expert opinion, the
following contraindications for FMT apply: anatomical abnormal-
ities that prevent safe application of FMT by endoscopy, enema or
tube; signs of intestinal perforation; pregnancy and severe food (e.
g., peanut) allergy. The latter may be solved by a patient‐related
donor with strict dietary restrictions before stool donation. Further
limitations appear mainly related to the mode of application.
Relative contraindications for upper gastrointestinal delivery are
increased risk of regurgitation (e.g., known large hiatus hernia,
severe gastro‐oesophageal reflux disease), swallowing disorders
and impaired small bowel motility or obstruction. An increased risk
of sedation may be considered a contraindication for lower
gastrointestinal delivery by colonoscopy.
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FMT for other indications
Both patients and clinicians are currently exploring the opportu-
nities for FMT to alter the course of a large variety of diseases.
Although promising studies that confirm the efficacy of FMT for
other disorders besides CDI are lacking, limited or contradicting
and FMT is not mentioned in treatment guidelines for disorders
beyond C. difficile infection. Although randomised trials suggest a
beneficial effect in a subset of patients with hepatic encephalop-
athy and ulcerative colitis, many questions about the optimal use
of FMT for those patients remain. For irritable bowel syndrome,
the results of randomised studies are less consistent. Until further
evidence becomes available, FMT for other indications should
preferably be limited to the research setting or, in the absence of
alternative therapeutic options, as compassionate use. The results




Although rare, the use of FMT in children suffering from CDI has
been described.101,102 Antibiotics remain the cornerstone of initial
CDI treatment, but recent European and American guidelines
recommend FMT for children suffering from multiple recurrent
CDI.2,103 FMT protocols for children and adults are similar. It is
unknown whether age‐matched donors should be considered for
paediatric use. Donor preparations from adults appear safe, but
long‐term effects are unknown and careful follow‐up is warranted.
Particular attention is required because the microbiota rapidly
develops during infancy, and maturation of the microbiota in
children occurs parallel with the maturation of the immune system;
processes which are likely to influence each other.104 Endoscopy
and the instillation of suspensions may be performed under gen-
eral anaesthesia with intubation.101,102 As for adults, existing
guidelines only recommend the use of FMT in children for recur-
rent CDI.2
Immunocompromised patients
FMT appears safe in immunocompromised patients.105 The recent
report of a severely immunocompromised patient's death following
transfer of an MDRO calls for particular caution in this patient
group.106 The risk of developing complications after the transfer of
potential pathogens appears increased in severely immunocom-
promised patients, defined as: (a) patients with current or fore-
seeable neutropenia within the next 14 days (defined as <500
neutrophils/ml); (b) patients scheduled for allogeneic stem cell
transplantation (SCT) or having received allogeneic SCT within
100 days; and (c) patients with active graft versus host
disease requiring immunosuppressive treatment. For severely
immunocompromised patients, we suggest: (a) additional screening
tests of donors; and (b) testing of the FMT preparation or donated
stool used for treatment of the individual patient, as described in
the Appendix (Supporting Information Material). For less severely
immunocompromised patients (<200 CD4 T cells/ml; or prolonged
use of corticosteroids at a mean dose of more than 0.3 mg/kg/day
of prednisone equivalent for over 3 weeks; or treatment with other
recognised T‐cell immunosuppressants, such as cyclosporin, TNF‐a
blockers, specific monoclonal antibodies (e.g., alemtuzumab), meth-
otrexate or nucleoside analogues during the past 90 days); or
inherited severe immunodeficiency (e.g., chronic granuloumatous
disease or severe combined immunodeficiency), normal donor
screening appears sufficient. More stringent follow‐up is justified in
all immunocompromised patients, and careful reporting of out-
comes and side effects is needed to confirm the safety of FMT in
those patients.
COVID 19‐pandemic
During the COVID‐19 pandemic, stool banks have to re‐evaluate
their working processing to optimise safety for donors, patients and
healthcare professionals, as outlined in a recent consensus report.107
Screening for SARS‐CoV‐2b should be incorporated in donor
screening protocols (Table 2).
Follow‐up of patients after FMT
Patients who receive FMT should be registered by the stool bank
with support of the treating FMT service, in order to document
patient flow, ensure traceability and document treatment outcome
and treatment‐related complications. A structured patient follow‐up
should be conducted. This should consist of clinical information and
relevant paraclinical tests, depending on the indication for FMT.
Short term follow‐up includes the documentation of side effects or
complications that occur in relation to the treatment or within the
first 24 h after any FMT‐related procedure. Long‐term follow‐up
includes the documentation of clinical details and relevant clinical
results beyond the first 24 h. The duration of long‐term follow‐up
depends on the indication, but should cover a minimum of 8 weeks
and preferably 6 months. Relevant clinical variables to document
during follow‐up are general symptoms, disease‐specific symptoms,
standardised symptom or disease activity scores and patient
weight.
FMT appears safe with limited side effects,21,108 although in-
fectious complications have been described in severely immuno-
compromised recipients underlining the need for careful donor
screening.106 However, some concern about the long‐term
side effects of FMT has been raised. This may include weight gain,
the development or worsening of inflammatory bowel diseases,
cancer, autoimmune diseases, allergies or neurological diseases.109
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Follow‐up should include clinical and analytical data, also deter-
mined by the indication for FMT and comorbidity of the patient.
National or institutional registries that are able to perform long‐
term follow‐up, and collect outcome data after FMT for various
conditions are warranted to document the long‐term safety of
FMT.
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1 Slightly decreased ESBL‐
E/CPE carriage
Abbreviations: CPE, Carbapenemase‐producing Enterobacteriaceae; ESBL, extended spectrum beta‐lactamase; FMT, faecal microbiota transplantation;
MDROs, multidrug resistant organisms; NA, not available; RCT, randomised controlled trial.
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CONCLUSIONS
FMT is a new, safe and efficacious treatment strategy. The critical
step of FMT is the process of donor selection and screening. Stool
banks have enabled centralisation of this process, following the
model of blood banks. We provide a model for the standardisation of
stool banking; key recommendations are summarised in Table 5.
Standardisation will result in further improvement of the quality and
safety of FMT in Europe. Finally, stool banks will enable quality
assurance of FMT and guarantee the availability of donor faeces
preparations for patients.
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TAB L E 5 Summary of key recommendations regarding FMT and stool banking
Regulatory framework
� FMT should be classified as “tissue transplantation”, not as a drug
� Stool banks should work in compliance with the EU tissue and cells directive
� Stool banks should have an organisational plan describing the intended activities and involved personnel
� An efficient and well protected data storage system for logging should be in place, allowing accurate tracing of the entire process from donor to
recipient
Donor recruitment, selection, screening
� Stool donation should remain a voluntary act
� In general, universal donors are preferred to patient‐selected donors
� Extensive screening of donors before releasing material for patient care is mandatory
� FMT products should be placed under quarantine until the donor has been found acceptable in a repeat screen
� All information collected during donor screening, including identity and results, should be stored for at least 30 years
Processing and storage of preparations
� Pooling of donor material is not recommended
� Long‐term storage of donor faeces preprations should be at −80°C
� A safety aliquot of each faecal suspension should be stored separately for up to 10 years after use
Clinical applications
� Currently, FMT is only considered standard of care in multiple recurrent CDI
� FMT can be used to treat multiple recurrent CDI in children or severely immunocompromised patients
� The choice for a route of delivery of FMT preparations should be based on local preferences and patient characteristics if applicable
Follow‐up
� Stool banks should actively perform follow‐up of all patients treated by FMT
� An FMT centre should maintain a register to document patient flow, performance, clinical outcome and safety measures
Abbreviations: CDI, Clostridioides difficile infection; FMT, faecal microbiota transplantation.
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